Hyerim Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hyerim Kim has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Hyerin Kim
Department of Laboratory Medicine, Pusan National University School of Medicine, Pusan National University Hospital, Busan, Korea
4 shared publications - In-Suk Kim
Pusan National University Yangsan Hospital
4 shared publications - Miyoung Kim
Department of Laboratory Medicine Asan Medical Center, University of Ulsan College of Medicine Seoul South Korea
3 shared publications - Boram Kim
Department of Laboratory Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea
2 shared publications - Byunggyu Bae
Department of Laboratory Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea
2 shared publications - Eunhui Ji
Pusan National University Yangsan Hospital
2 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by Laboratory Medicine Online in Laboratory Medicine Online
- Vol. 16 (4) , 269-278
Current Guidelines for the Laboratory Detection and Interpretation of Lupus Anticoagulant
Hyerim Kim, M.D.. Lab Med Online 2026;16:269-78. https://doi.org/10.47429/lmo.2026.16.4.269
- 1 October 2026
- Published by Laboratory Medicine Online in Laboratory Medicine Online
- Vol. 16 (4) , 269-278
Open AccessCurrent Guidelines for the Laboratory Detection and Interpretation of Lupus Anticoagulant
Hyerim Kim, M.D.. Lab Med Online 2026;16:269-78. https://doi.org/10.47429/lmo.2026.16.4.269
- Open Access
- 10 August 2026
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
Implications of Incorporating Myelodysplasia-Related Gene Variant Data on Acute Myeloid Leukemia Reclassification According to WHO-HAEM5 and ICC: A Large Multicenter Korean Cohort Study
Yu Jeong Choi, M.D., Ph.D., Jee-Soo Lee, M.D., Ph.D., Saeam Shin, M.D., Ph.D., In-Suk Kim, M.D., Ph.D., Hyun-Young Kim, M.D., Ph.D., Boram Kim, M.D., Ph.D., Hee-Jin Kim, M.D., Ph.D., Eunhui Ji, M.D., Ph.D., Hyerin Kim, M.D., Ph.D., Hyerim Kim, M.D., Ph.D., Byunggyu Bae, M.D., Ph.D., Yonggoo Kim, M.D., Ph.D., Jong-Mi Lee, M.D., Ph.D., Yoon Hwan Chang, M.D., Ph.D., Hyun Kyung Kim, M.D., Ph.D., Ja Young Lee, M.D., Ph.D., Shinae Yu, M.D., Ph.D., Miyoung Kim, M.D., Ph.D., Young-Uk Cho, M.D., Ph.D., Seongsoo Jang, M.D., Ph.D., and Myungshin Kim, M.D., Ph.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2026.0043
- 10 August 2026
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
Open AccessImplications of Incorporating Myelodysplasia-Related Gene Variant Data on Acute Myeloid Leukemia Reclassification According to WHO-HAEM5 and ICC: A Large Multicenter Korean Cohort Study
Yu Jeong Choi, M.D., Ph.D., Jee-Soo Lee, M.D., Ph.D., Saeam Shin, M.D., Ph.D., In-Suk Kim, M.D., Ph.D., Hyun-Young Kim, M.D., Ph.D., Boram Kim, M.D., Ph.D., Hee-Jin Kim, M.D., Ph.D., Eunhui Ji, M.D., Ph.D., Hyerin Kim, M.D., Ph.D., Hyerim Kim, M.D., Ph.D., Byunggyu Bae, M.D., Ph.D., Yonggoo Kim, M.D., Ph.D., Jong-Mi Lee, M.D., Ph.D., Yoon Hwan Chang, M.D., Ph.D., Hyun Kyung Kim, M.D., Ph.D., Ja Young Lee, M.D., Ph.D., Shinae Yu, M.D., Ph.D., Miyoung Kim, M.D., Ph.D., Young-Uk Cho, M.D., Ph.D., Seongsoo Jang, M.D., Ph.D., and Myungshin Kim, M.D., Ph.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2026.0043
- Open Access
- 9 May 2026
- Published by Elsevier in Practical Laboratory Medicine
- Vol. 50, e00538
Analytical performance evaluation and method comparison of the 1copy BCR::ABL1 qPCR assay for monitoring chronic myeloid leukemia
- 9 May 2026
- Published by Elsevier in Practical Laboratory Medicine
- Vol. 50, e00538
Open AccessAnalytical performance evaluation and method comparison of the 1copy BCR::ABL1 qPCR assay for monitoring chronic myeloid leukemia
- Open Access
- 7 July 2025
- Published by Springer Nature in Blood Research
- Vol. 60 (1) , 1-9
Real-world apixaban concentration in Korean patients with atrial fibrillation
Purpose: Apixaban is recommended for patients with atrial fibrillation. Although routine monitoring of plasma concentrations is not typically advised, factors such as ethnicity, sex, and comorbidities can influence these levels. Our study analyzed the plasma apixaban concentrations (PAC) in patients to explore whether these levels, along with underlying conditions, offer enhanced insights for risk stratification. Methods: This study analyzed 49 patients with atrial fibrillation who had been taking apixaban for over a month, examined factor Xa levels within 6 h post-administration, and correlated PAC with clinical characteristics such as age, body weight, estimated glomerular filtration rate (eGFR), presence of heart failure, and bleeding events. Results: The mean plasma concentration of apixaban in all patients was 160.3 ± 77.5 ng/mL. Those taking apixaban 5 mg twice daily had higher plasma concentrations than those taking 2.5 mg twice daily (191.2 ± 75.3 ng/mL vs. 137.2 ± 72.0 ng/mL, p = 0.014). Among the patients receiving a reduced dose, renal function and heart failure were significantly associated with plasma concentrations. No factors were associated with the plasma concentrations in patients receiving the standard dose. Notably, reduced-dose patients with heart failure had plasma concentrations comparable to those of individuals receiving the standard dose and exhibited a higher incidence of bleeding than the other groups. Conclusions: PAC measurement revealed that apixaban dosages, classified based on age, body weight, and eGFR, were generally effective. Nonetheless, heart failure may increase plasma levels and correlate with an increased bleeding risk in Korean patients on reduced doses. Therefore, tailoring apixaban prescriptions to account for heart failure and other comorbidities may enhance treatment efficacy.
- 7 July 2025
- Published by Springer Nature in Blood Research
- Vol. 60 (1) , 1-9
Open AccessReal-world apixaban concentration in Korean patients with atrial fibrillation
Purpose: Apixaban is recommended for patients with atrial fibrillation. Although routine monitoring of plasma concentrations is not typically advised, factors such as ethnicity, sex, and comorbidities can influence these levels. Our study analyzed the plasma apixaban concentrations (PAC) in patients to explore whether these levels, along with underlying conditions, offer enhanced insights for risk stratification. Methods: This study analyzed 49 patients with atrial fibrillation who had been taking apixaban for over a month, examined factor Xa levels within 6 h post-administration, and correlated PAC with clinical characteristics such as age, body weight, estimated glomerular filtration rate (eGFR), presence of heart failure, and bleeding events. Results: The mean plasma concentration of apixaban in all patients was 160.3 ± 77.5 ng/mL. Those taking apixaban 5 mg twice daily had higher plasma concentrations than those taking 2.5 mg twice daily (191.2 ± 75.3 ng/mL vs. 137.2 ± 72.0 ng/mL, p = 0.014). Among the patients receiving a reduced dose, renal function and heart failure were significantly associated with plasma concentrations. No factors were associated with the plasma concentrations in patients receiving the standard dose. Notably, reduced-dose patients with heart failure had plasma concentrations comparable to those of individuals receiving the standard dose and exhibited a higher incidence of bleeding than the other groups. Conclusions: PAC measurement revealed that apixaban dosages, classified based on age, body weight, and eGFR, were generally effective. Nonetheless, heart failure may increase plasma levels and correlate with an increased bleeding risk in Korean patients on reduced doses. Therefore, tailoring apixaban prescriptions to account for heart failure and other comorbidities may enhance treatment efficacy.
- Open Access
- 5 November 2024
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 45 (2) , 160-169
TP53 Mutation Status in Myelodysplastic Neoplasm and Acute Myeloid Leukemia: Impact of Reclassification Based on the 5th WHO and International Consensus Classification Criteria: A Korean Multicenter Study
Hyun-Young Kim, M.D., Saeam Shin, M.D., Jong-Mi Lee, M.D., Ph.D., In-Suk Kim, M.D., Ph.D., Boram Kim, M.D., Hee-Jin Kim, M.D., Yu Jeong Choi, M.D., Byunggyu Bae, M.D., Yonggoo Kim, M.D., Eunhui Ji, M.D., Hyerin Kim, M.D., Hyerim Kim, M.D., Jee-Soo Lee, M.D., Yoon Hwan Chang, M.D., Hyun Kyung Kim, M.D., Ja Young Lee, M.D., Shinae Yu, M.D., Miyoung Kim, M.D., Young-Uk Cho, M.D., Seongsoo Jang, M.D., and Myungshin Kim, M.D.. Ann Lab Med 2025;45:160-9. https://doi.org/10.3343/alm.2024.0351
- 5 November 2024
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 45 (2) , 160-169
Open AccessTP53 Mutation Status in Myelodysplastic Neoplasm and Acute Myeloid Leukemia: Impact of Reclassification Based on the 5th WHO and International Consensus Classification Criteria: A Korean Multicenter Study
Hyun-Young Kim, M.D., Saeam Shin, M.D., Jong-Mi Lee, M.D., Ph.D., In-Suk Kim, M.D., Ph.D., Boram Kim, M.D., Hee-Jin Kim, M.D., Yu Jeong Choi, M.D., Byunggyu Bae, M.D., Yonggoo Kim, M.D., Eunhui Ji, M.D., Hyerin Kim, M.D., Hyerim Kim, M.D., Jee-Soo Lee, M.D., Yoon Hwan Chang, M.D., Hyun Kyung Kim, M.D., Ja Young Lee, M.D., Shinae Yu, M.D., Miyoung Kim, M.D., Young-Uk Cho, M.D., Seongsoo Jang, M.D., and Myungshin Kim, M.D.. Ann Lab Med 2025;45:160-9. https://doi.org/10.3343/alm.2024.0351
- 24 September 2024
- Published by Springer Nature in memo - Magazine of European Medical Oncology
- Vol. 18 (1) , 53-55
Unclassifiable acute leukemia with blastic plasmacytoid dendritic cell neoplasm: deciding on the appropriate therapy
- 24 September 2024
- Published by Springer Nature in memo - Magazine of European Medical Oncology
- Vol. 18 (1) , 53-55
Unclassifiable acute leukemia with blastic plasmacytoid dendritic cell neoplasm: deciding on the appropriate therapy
- Open Access
- 26 December 2023
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 44 (3) , 222-234
Current Status of Flow Cytometric Immunophenotyping of Hematolymphoid Neoplasms in Korea
Mikyoung Park, M.D., Ph.D., Jihyang Lim, M.D., Ph.D., Ari Ahn, M.D., Ph.D., Eun-Jee Oh, M.D., Ph.D., Jaewoo Song, M.D., Ph.D., Kyeong-Hee Kim, M.D., Ph.D., Jin-Yeong Han, M.D., Ph.D., Hyun-Woo Choi, M.D., Ph.D., Joo-Heon Park, M.D., Kyung-Hwa Shin, M.D., Ph.D., Hyerim Kim, M.D., Ph.D., Miyoung Kim, M.D., Ph.D., Sang-Hyun Hwang, M.D., Ph.D., Hyun-Young Kim, M.D., Ph.D., Duck Cho, M.D., Ph.D., and Eun-Suk Kang, M.D., Ph.D.. Ann Lab Med 2024;44:222-34. https://doi.org/10.3343/alm.2023.0298
- 26 December 2023
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 44 (3) , 222-234
Open AccessCurrent Status of Flow Cytometric Immunophenotyping of Hematolymphoid Neoplasms in Korea
Mikyoung Park, M.D., Ph.D., Jihyang Lim, M.D., Ph.D., Ari Ahn, M.D., Ph.D., Eun-Jee Oh, M.D., Ph.D., Jaewoo Song, M.D., Ph.D., Kyeong-Hee Kim, M.D., Ph.D., Jin-Yeong Han, M.D., Ph.D., Hyun-Woo Choi, M.D., Ph.D., Joo-Heon Park, M.D., Kyung-Hwa Shin, M.D., Ph.D., Hyerim Kim, M.D., Ph.D., Miyoung Kim, M.D., Ph.D., Sang-Hyun Hwang, M.D., Ph.D., Hyun-Young Kim, M.D., Ph.D., Duck Cho, M.D., Ph.D., and Eun-Suk Kang, M.D., Ph.D.. Ann Lab Med 2024;44:222-34. https://doi.org/10.3343/alm.2023.0298
- Open Access
- 1 July 2023
- Published by Laboratory Medicine Online in Laboratory Medicine Online
- Vol. 13 (3) , 172-181
Concordance of Current Tests Used for the Diagnosis of Bone Marrow Involvement in B-Lineage Lymphoma with Respect to Various Lymphoma Grade
Sang Hyuk Park, M.D., Seulgi Moon, M.D., Hyerim Kim, M.D., In-Suk Kim, M.D.. Lab Med Online 2023;13:172-81. https://doi.org/10.47429/lmo.2023.13.3.172
- 1 July 2023
- Published by Laboratory Medicine Online in Laboratory Medicine Online
- Vol. 13 (3) , 172-181
Open AccessConcordance of Current Tests Used for the Diagnosis of Bone Marrow Involvement in B-Lineage Lymphoma with Respect to Various Lymphoma Grade
Sang Hyuk Park, M.D., Seulgi Moon, M.D., Hyerim Kim, M.D., In-Suk Kim, M.D.. Lab Med Online 2023;13:172-81. https://doi.org/10.47429/lmo.2023.13.3.172
- Open Access
- 30 June 2023
- Published by Korean Association of Quality Assurance for Clinical Laboratory in Journal of Laboratory Medicine and Quality Assurance
- Vol. 45 (2) , 58-64
Impact of Autoverification in the Hematology Laboratory: Experience with LimasVfy
Sang Hyuk Park, Heejeong Kim, Hyerin Kim, and Hyerim Kim. Lab Med Qual Assur 2023;45:58-64. https://doi.org/10.15263/jlmqa.2023.45.2.58
- 30 June 2023
- Published by Korean Association of Quality Assurance for Clinical Laboratory in Journal of Laboratory Medicine and Quality Assurance
- Vol. 45 (2) , 58-64
Open AccessImpact of Autoverification in the Hematology Laboratory: Experience with LimasVfy
Sang Hyuk Park, Heejeong Kim, Hyerin Kim, and Hyerim Kim. Lab Med Qual Assur 2023;45:58-64. https://doi.org/10.15263/jlmqa.2023.45.2.58
- Open Access
- 21 April 2023
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 43 (5) , 470-476
Pre-transfusion Testing Using Crossmatching Agglutination Reaction Grades Combined With Rh Subgroup Phenotyping in Patients With Autoantibodies: A Three-year Experience at a Tertiary Hospital
Jongmin Kim, M.D., Kyung-Hwa Shin, M.D., Ph.D., Hyerim Kim, M.D., Ph.D., Hyung-Hoi Kim, M.D., Ph.D., and Hyun-Ji Lee, M.D., Ph.D.. Ann Lab Med 2023;43:470-6. https://doi.org/10.3343/alm.2023.43.5.470
- 21 April 2023
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 43 (5) , 470-476
Open AccessPre-transfusion Testing Using Crossmatching Agglutination Reaction Grades Combined With Rh Subgroup Phenotyping in Patients With Autoantibodies: A Three-year Experience at a Tertiary Hospital
Jongmin Kim, M.D., Kyung-Hwa Shin, M.D., Ph.D., Hyerim Kim, M.D., Ph.D., Hyung-Hoi Kim, M.D., Ph.D., and Hyun-Ji Lee, M.D., Ph.D.. Ann Lab Med 2023;43:470-6. https://doi.org/10.3343/alm.2023.43.5.470